University of Southampton
Synthesis, biodistribution and efficacy of monomeric and multimeric antisense oligonucleotides in visceral tissue and the central nervous system
Abstract
dc:description.abstractSynthesis, biodistribution and efficacy of monomeric and multimeric<br/>antisense oligonucleotides in visceral tissue and the central nervous system<br/>Antisense oligonucleotides (ASOs) are a promising class of therapeutics for<br/>treating diseases of a genetic origin. ASOs are able to modulate the<br/>expression of disease-causing RNA, interact with the immune system and<br/>affect the endogenous regulation of genes. ASOs are, however, poorly taken<br/>up into some tissue types which limits their potential therapeutic benefit.<br/>This work aimed to improve the biodistribution and efficacy of antisense<br/>oligonucleotides by synthesising them as dendrimers - discrete structures<br/>comprising multiple oligonucleotides around a central core. Hence, the<br/>various synthetic approaches are described for attempts to access these<br/>molecules, their effects on in vitro and in vivo distribution and silencing<br/>of the long non-coding RNA MALAT1. It is demonstrated that larger<br/>dendrimers are more rapidly taken up into cultured cells than monomeric<br/>oligomers and that the compounds distribute differently in the mouse.<br/>Nevertheless, silencing efficacy both in vitro and in vivo seems to peak<br/>with monomeric or dimeric structures. It is anticipated that the rapid<br/>uptake of these dendrimers may be able to be translated into improved<br/>silencing by modifying their chemistry in the future.<br/><br/>To adequately assay the biodistribution of these oligonucleotides, the<br/>available techniques discussed in the literature are compared. Dissatisfied<br/>with the current state of the art, the process of preparing a polyclonal<br/>antibody directed against the chemically modified backbone found in most<br/>therapeutic oligonucleotides is described. It is shown that the antibody<br/>generated is able to be used for immunohistochemistry and<br/>immunofluorescence, and that it shows promise for use as a quantitative<br/>assay for determining oligonucleotide concentration in tissue.<br/><br/>Finally, efforts in improving oligonucleotide chemistry and structure for<br/>silencing disease-causing RNA in the CNS are described. Using C9ORF72<br/>repeat-expanded Amyotrophic Lateral Sclerosis as a target disease, it is<br/>show that some oligonucleotides are intrinsically and surprisingly toxic on<br/>central administration and that this toxicity can be ameliorated by<br/>reduction of the phosphorothioate content of the backbone. The generation<br/>of a preclinical lead compound is described that will, building on this<br/>work, be screened for toxicity in non-human primates and advanced to a<br/>compassionate care trial in two patients, pending FDA approval.
Degree
thesis:*- Name dc:type.qualificationname
- Ph.D.
- Level dc:type.qualificationlevel
- doctoral
- Grantor dc:publisher.institution
- University of Southampton
- Year dc:date.issued
- 2018
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Moazami, Michael
- Advisor dc:contributor.advisor
-
- Watts, Jonathan K.
Rights
- Language dc:language
- English, eng